Journal of Addictive Diseases
Overview
The Journal of Addictive Diseases is a peer-reviewed publication dedicated to advancing the understanding and treatment of addictive disorders. It provides a platform for researchers, clinicians, and policymakers to share their findings and insights on various aspects of addiction, including prevention, intervention, and recovery. The journal covers a wide range of addictive substances and behaviors, offering evidence-based approaches and innovative strategies to address the challenges posed by addiction.
Details
Details
Abbr.
J Addict Dis
Publisher
Informa Healthcare
Start
1991
End
Continuing
Frequency
Quarterly
p-ISSN
1055-0887
e-ISSN
1545-0848
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 5296
68
SJR / Ranks: 6420
691
CiteScore / Ranks: 8773
2.90
Recent Articles
1.
Caponnetto P, Lanzafame I, Prezzavento G, Rawashdeh S, Moussa M, Fakhrou A
J Addict Dis
. 2025 Mar;
:1-22.
PMID: 40079231
TikTok's rapid rise has spurred concerns about its potential to cause problematic use behaviors, which some consider akin to addiction. This systematic review seeks to understand the diagnostic and therapeutic...
2.
Mamat R, Ibrahim B, Rashid R, Sim Maw Shin G, Wahab S, Ahmad A, et al.
J Addict Dis
. 2025 Mar;
:1-12.
PMID: 40050248
Amphetamine-type stimulants (ATS), such as methamphetamine, amphetamine, and MDMA, are highly risky substances linked to neurochemical disruptions, metabolic disturbances, and systemic toxicity. Despite substantial research on their neurotoxic effects, the...
3.
4.
Lomas C
J Addict Dis
. 2025 Mar;
:1-22.
PMID: 40050232
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological...
5.
Jeong H, Johnson K, Robertson E, Aaflaq A, McDaniel J, McIntosh S, et al.
J Addict Dis
. 2025 Feb;
:1-9.
PMID: 39972565
Background: The current study uses geographic information system (GIS) methods to better understand structural risks significantly associated with substance misuse and how those risks may be driven by urbanicity versus...
6.
Podwojniak A, Chen K, Pullinger B, Jabon J, Garcia A, Jermyn R
J Addict Dis
. 2025 Feb;
:1-5.
PMID: 39930799
Oxymetazoline hydrochloride 0.05% is a lipophilic sympathomimetic nasal decongestant spray available over the counter (OTC) and commonly used for allergic and chronic rhinitis. A well-known side effect of these nasal...
7.
Serfilippi T, Piccirillo S, Romagnoli F, Tarini M, Lariccia V, Magi S
J Addict Dis
. 2025 Feb;
:1-5.
PMID: 39910803
Methadone maintenance therapy is the cornerstone of treatment for heroin addiction. Hyperhidrosis is a common and often-overlooked side effect of methadone. Different medications, such as antihistamines and anticholinergic drugs, have...
8.
Sharma G, Wade Q, Graziane N
J Addict Dis
. 2025 Jan;
1-17.
PMID: 39834150
Opioid use disorder (OUD) is associated with a reduction in brain white matter, affecting critical areas involved in decision-making, impulse control, and reward processing. The FDA has approved several drugs...
9.
Chuang J, Lide R, Kamath N, Oliveto A, Addicott M
J Addict Dis
. 2025 Jan;
1-5.
PMID: 39834135
Objectives: There is increasing evidence of ketamine's therapeutic potential in reducing substance use in individuals with substance use disorders. However, its effects on tobacco use disorder are unknown. We investigated...
10.
Webber H, Badawi J, Calvillo D, Yoon J, Weaver M, Lane S, et al.
J Addict Dis
. 2024 Dec;
:1-8.
PMID: 39731508
No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved for insomnia treatment, reduces MA self-administration and MA-induced...